All questionsDrug interactions: Foundayo (orforglipron) in chronic weight management7 questions · 1 sourceDrug interactionsWhat drug interactions does Foundayo have?“Strong CYP3A4 Inhibitors: The maximum dosage of FOUNDAYO is 9 mg once daily when used concomitantly with a strong CYP3A4 inhibitor. Avoid concomitant use with strong CYP3A4 inhibitors that also inhibit OATP1B. (7.1) CYP3A4 Inducers: Avoid concomitant use with strong CYP3A4 inducers. Monitor FOUNDAYO effectiveness and escalate dosage as needed when used concomitantly with moderate CYP3A4 inducers. (7.1) Simvastatin: Do not exceed simvastatin 20 mg once daily when used concomitantly with FOUNDAYO. (7.2) FOUNDAYO delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. (7.3)” (opens the source at this quote in a new tab)CopyFlag“Table 3: Clinically Relevant Effects of FOUNDAYO on Other Drugs Simvastatin Intervention Do not exceed simvastatin 20 mg once daily when concomitantly used with FOUNDAYO. Clinical Impact Use of FOUNDAYO with simvastatin increased exposure of the active metabolite simvastatin acid two-fold [see Clinical Pharmacology (12.3)]. A two-fold increase in simvastatin acid exposure at the highest simvastatin dose could be clinically meaningful. Insulin or Insulin Secretagogue (e.g., Sulfonylurea) Intervention When initiating FOUNDAYO, consider reducing the dose of concomitantly administered insulin or insulin secretagogues (e.g., sulfonylureas) [see Warnings and Precautions (5.5)]. Clinical Impact FOUNDAYO stimulates insulin release in the presence of elevated blood glucose concentrations which could increase the risk for hypoglycemia when used in combination with insulin or insulin secretagogues.” (opens the source at this quote in a new tab)CopyFlagNote: The first passage is the Drug Interactions summary in the highlights of the Prescribing Information; the second is Table 3 of section 7.2.How do CYP3A4 inhibitors and inducers change Foundayo levels?“Table 4 outlines the results of definitive clinical trials and physiologically based pharmacokinetic (PBPK) simulations assessing the effect of other drugs on orforglipron pharmacokinetics. Concomitant use of strong CYP3A4 inhibitors significantly increased exposure of orforglipron while concomitant use of moderate or strong CYP3A4 inducers led to reductions in orforglipron exposure [see Dose and Administration (2.2), Drug Interactions (7.1)].” (opens the source at this quote in a new tab)CopyFlag“Table 4: Potential for Other Drugs to Affect FOUNDAYO a Simulated using physiologically based pharmacokinetic modeling. Concomitant Drug Category Concomitant Drug (Dose) Change in Orforglipron AUC Cmax Strong CYP3A4 inhibitors Clarithromycin (500 mg twice daily) ↑3.5-fold ↑1.9-fold Moderate CYP3A4 inhibitors Verapamila (80 mg three times daily) ↑2-fold ↑1.6-fold Strong CYP3A4 inducers Carbamazepine (300 mg twice daily) ↓82% ↓55% Moderate CYP3A4 inducers Efavirenza (600 mg once daily) ↓61% ↓33% Weak CYP3A4 inducers Modafinila (200 mg once daily) ↓16% ↓7% OATP1B inhibitors Cyclosporine (200 mg twice daily) ↑2.6-fold ↑1.3-fold P-gp inhibitors Quinidine (200 mg twice daily) ↓12% ↓26% Acid reducing agents Esomeprazole (40 mg once daily) No effect No effect” (opens the source at this quote in a new tab)CopyFlag“Table 2: Clinically Relevant Effects of Other Drugs on FOUNDAYO Strong CYP3A4 Inhibitors Intervention The maximum dosage of FOUNDAYO is 9 mg once daily when used concomitantly with a strong CYP3A4 inhibitor. Avoid concomitant use of FOUNDAYO with strong CYP3A4 inhibitors that also inhibit OATP1B (e.g., ritonavir) [see Dosage and Administration (2.2)]. Clinical Impact CYP3A4 inhibitors increase FOUNDAYO exposure [see Clinical Pharmacology (12.3)], which may increase the risk of FOUNDAYO-associated adverse reactions. Strong CYP3A4 inhibitors that also clinically inhibit OATP1B are expected to significantly increase plasma concentrations of FOUNDAYO, which may increase the risk of FOUNDAYO-associated adverse reactions [see Warnings and Precautions (5.3), Adverse Reactions (6.1)]. Strong CYP3A4 Inducers Intervention Avoid concomitant use of FOUNDAYO with strong CYP3A4 inducers. Clinical Impact Induction of CYP3A4 decreases FOUNDAYO exposure [see Clinical Pharmacology (12.3)], which may reduce the effectiveness of FOUNDAYO. Moderate CYP3A4 Inducers Intervention Monitor FOUNDAYO effectiveness and escalate dosage as needed when used concomitantly with moderate CYP3A4 inducers [see Dosage and Administration (2.1)]. Clinical Impact Induction of CYP3A4 decreases FOUNDAYO exposure [see Clinical Pharmacology (12.3)], which may reduce the effectiveness of FOUNDAYO.” (opens the source at this quote in a new tab)CopyFlagNote: In Table 4, footnote a marks results simulated using physiologically based pharmacokinetic modeling (verapamil, efavirenz, and modafinil).Can Foundayo be taken with simvastatin, atorvastatin, or rosuvastatin?“Simvastatin Intervention Do not exceed simvastatin 20 mg once daily when concomitantly used with FOUNDAYO. Clinical Impact Use of FOUNDAYO with simvastatin increased exposure of the active metabolite simvastatin acid two-fold [see Clinical Pharmacology (12.3)]. A two-fold increase in simvastatin acid exposure at the highest simvastatin dose could be clinically meaningful.” (opens the source at this quote in a new tab)CopyFlag“Table 5 outlines the results of clinical assessments that evaluated the effect of orforglipron on other drugs. Concomitant use of orforglipron and simvastatin led to significant increases in the active metabolite simvastatin acid whether orforglipron was co-administered or dosing was staggered by 2 hours [see Drug Interactions (7.2)]. No clinically relevant changes were observed for orforglipron when used with rosuvastatin or atorvastatin.” (opens the source at this quote in a new tab)CopyFlagDoes Foundayo make birth control pills less effective?“Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 30 days after initiation with FOUNDAYO and for 30 days after each dose escalation. Hormonal contraceptives that are not administered orally should not be affected.” (opens the source at this quote in a new tab)CopyFlag“The effect of FOUNDAYO on the absorption of oral contraceptives has not been evaluated in a clinical trial.” (opens the source at this quote in a new tab)CopyFlagDoes Foundayo affect the absorption of other oral medications?“FOUNDAYO delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications [see Clinical Pharmacology (12.3)].” (opens the source at this quote in a new tab)CopyFlag“Orforglipron delays gastric emptying and has the potential to affect the rate of absorption of other concomitantly administered oral drugs. The gastric emptying delay effect of orforglipron on acetaminophen Cmax was largest after the first dose of FOUNDAYO 0.8 mg with acetaminophen Cmax decreased by 28%. The effect diminished after repeated dosing of FOUNDAYO 17.2 mg.” (opens the source at this quote in a new tab)CopyFlagCan Foundayo be taken with insulin or a sulfonylurea?“Insulin or Insulin Secretagogue (e.g., Sulfonylurea) Intervention When initiating FOUNDAYO, consider reducing the dose of concomitantly administered insulin or insulin secretagogues (e.g., sulfonylureas) [see Warnings and Precautions (5.5)]. Clinical Impact FOUNDAYO stimulates insulin release in the presence of elevated blood glucose concentrations which could increase the risk for hypoglycemia when used in combination with insulin or insulin secretagogues.” (opens the source at this quote in a new tab)CopyFlagCan Foundayo be used with another GLP-1 receptor agonist?“Concomitant use with another GLP-1 receptor agonist is not recommended.” (opens the source at this quote in a new tab)CopyFlag“FOUNDAYO should not be used with other GLP-1 receptor agonist medicines.” (opens the source at this quote in a new tab)CopyFlagNote: The second passage is from the Medication Guide printed with the Prescribing Information.